EUCTR2018-000916-75-BE进行中（未招募）1 期
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination with Filgrastim in Early Recovery Post-Myocardial Infarction - REC-DUT-002
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female born between 1933 and 2000.
- •2. Body weight <96 kg (~212 lb).
- •3.Able to provide written informed consent, including signing and dating the informed consent form (ICF).
- •4.Diagnosis of STEMI (defined as new ST-segment elevation at the J point of at least 2 continuous leads of >2 mm [0.2 mV] in men or >1.5 mm [0.1 mV] in women in leads V2 and V3 OR >1 mm in any other contiguous precordial leads or the limb leads [for both men and women]) with PCI (bare metal or drug-eluting stent) and Thrombolysis in Myocardial Infarction flow grade 2 or 3 occurring >2 hours and <24 hours after symptom onset.
- •5.LVEF =45% obtained by cECHO performed within 36 hours post-stent placement.
- •6.Receiving standard medical therapy for post-myocardial infarction (MI) treatment, according to local procedures and PI discretion.
- •7.Female subjects of childbearing potential must have a negative serum pregnancy test at Screening and an additional negative urine pregnancy test prior to the first dose of IMP unless regulated differently by national legislation.
- •8.Sexually active female subjects of childbearing potential (i.e., women who are not postmenopausal or who have not had a bilateral oophorectomy, hysterectomy, or tubal ligation) and all male subjects (who have not been surgically sterilized by vasectomy) must agree to use effective contraception during the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •1.Previous MI prior to Screening.
- •2.Complex peri/post-MI clinical course, including arrhythmias, cardiogenic shock, pulmonary edema requiring mechanical ventilation, or requirement for vasopressor medications.
- •3.Significant pre-existing cardiomyopathy with known LVEF =45% or moderate to severe mitral or aortic valvular disease.
- •4.Amyloidosis, hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, or constrictive pericarditis.
- •5.Existing heart transplant.
- •6.Ventricular tachycardia or fibrillation not associated with an acute ischemic episode.
- •7.Uncontrolled hypertension (systolic >180 mmHg or diastolic >120 mmHg).
- •8.Treatment with any DPP4 inhibitors (e.g., alogliptin, linagliptin, vildagliptin, saxagliptin, sitagliptin) or granulocyte-colony stimulating factor medication (e.g., filgrastim, lenograstim, pegfilgrastim, lipegfilgrastim) within 4 months prior to Randomization.
- •9.Contraindication to treatment with filgrastim, including known allergy to filgrastim or other G-CSF medication.
- •10.Anemia defined as hemoglobin <9 g/dL prior to Randomization.
- •11.Thrombocytosis (platelets >500 k/uL).
- •12.Known positive serology for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).
- •13.Alanine aminotransferase (ALT) concentrations >3 times the upper limit of normal (ULN) or bilirubin >2 x ULN prior to Randomization, according to local laboratory assessments.
- •14.History of cirrhosis and Child-Pugh score B or C.
- •15.Current fever greater than 101.4 °F (38.6 °C) or recent systemic infection within 2 weeks prior to Randomization.
- •16.Contraindication to cMRI procedure, including prior implantable cardioverter defibrillator placement, known reaction to gadolinium, claustrophobia, non-MRI-compatible, cochlear implant, obesity, or presence of ferromagnetic material including shunts, shrapnel, penile prostheses, or blood vessel coil.
- •17.Pregnant, planning to become pregnant, or nursing female subjects.
- •18.Autoimmune disease requiring immunosuppressive therapy or chronic steroid treatment >5 mg/day prednisolone or equivalent.
- •19.Significant renal impairment defined as estimated glomerular filtration rate <45 mL/min/1.73 m2, using the Chronic Kidney Disease Epidemiology Collaboration equation.
- •20.Active neoplasm requiring surgery, chemotherapy, or radiation within the prior 12 months (subjects with a history of malignancy who have undergone curative resection or otherwise not requiring treatment for at least 12 months prior to Screening with no detectable recurrence are allowed).
- •21.Malignant hematological disease, i.e., chronic myeloid leukemia or myelodysplastic syndrome.
- •22.History of cerebrovascular accident or transient ischemic attack in the past 6 months.
- •23.History of pneumonia in the last 4 weeks.
- •24.History of any significant medical or psychiatric disorder that in the opinion of the investigator would make the subject unsuitable for participation in the study.
- •25.Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) or treatment with an investigational biologic drug within 6 weeks prior to randomization.
- •26.Participation in another concurrent clinical trial involving a therapeutic intervention (participation in observational studies and/or registry studies is permitted).
- •27.Unable or unwilling to comply with the requirements of the study.
- •28. Subject and/or an immediate family member is an employee of the investigational site directly affiliated with this stud
研究者
相似试验
进行中（未招募）
1 期
Clinical Study of Inhaled GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)Pulmonary Arterial Hypertension (PAH)MedDRA version: 20.0Level: LLTClassification code 10077739Term: Pulmonary arterial hypertension WHO functional class ISystem Organ Class: 100000004855EUCTR2019-002669-37-ATGB002, Inc.80
进行中（未招募）
1 期
A Phase 2 Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection FractioHeart failure (HF) with reduced ejection fraction (HFrEF)MedDRA version: 26.1Level: LLTClassification code: 10078289Term: Heart failure with reduced ejection fraction Class: 10007541CTIS2023-508736-62-00Cardurion Pharmaceuticals Inc.400
进行中（未招募）
1 期
This is a Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid TreatmentSubjects with Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid TreatmentMedDRA version: 21.0Level: PTClassification code 10036099Term: Polymyalgia rheumaticaSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2021-000648-23-DEAbbVie Deutschland GmbH & Co. KG160
招募中
1 期
Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitislcerative ColitisMedDRA version: 20.1Level: LLTClassification code: 10045365Term: Ulcerative colitis Class: 10017947CTIS2023-508679-34-00Anaptysbio Inc.147
进行中（未招募）
1 期
This is a Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid TreatmentSubjects with Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid TreatmentMedDRA version: 21.0Level: PTClassification code 10036099Term: Polymyalgia rheumaticaSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2021-000648-23-ITABBVIE DEUTSCHLAND GMBH & CO. KG200